Scholarlink

<p>Ischemia-reperfusion injury (IRI) is a critical pathological process affecting multiple organs, including the heart, brain, kidney, and liver. Recent studies have highlighted the dual roles of AlkB homolog 5 (ALKBH5), an N6-methyladenosine (m⁶A) RNA demethylase, in regulating cellular responses to IRI through epigenetic mechanisms. This review synthesizes current evidence on ALKBH5 involvement in metabolic reprogramming, autophagy, apoptosis, pyroptosis, and inflammation across organ-specific IRI models. We establish a unifying framework in which ALKBH5 functions as a double-edged sword, exerting either protective effects (such as sirtuin 1 (SIRT1) activation in the heart) or detrimental outcomes (such as tricarboxylic acid (TCA) cycle suppression), depending on tissue-specific microenvironments, disease stage dynamics, and downstream effector crosstalk (e.g., TCA cycle, SIRT1, PANoptosis). Despite its therapeutic potential, challenges in translation persist due to ALKBH5’s bidirectional effects and the lack of tissue-specific delivery systems. Future research should aim to resolve these controversies through advanced techniques such as single-cell m⁶A epitranscriptomics and develop spatiotemporally targeted modulators for precise intervention.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Emerging Dual Roles of ALKBH5 in Ischemia-reperfusion Injury: Mechanisms and Therapeutic Implications

  • 期刊论文

  • 发表日期：

    2025年10月29日

查看全文
  • Chenglin Zhu,
  • Hao Fan,
  • Qi Zhang,
  • Honggang Wang

摘要

Ischemia-reperfusion injury (IRI) is a critical pathological process affecting multiple organs, including the heart, brain, kidney, and liver. Recent studies have highlighted the dual roles of AlkB homolog 5 (ALKBH5), an N6-methyladenosine (m⁶A) RNA demethylase, in regulating cellular responses to IRI through epigenetic mechanisms. This review synthesizes current evidence on ALKBH5 involvement in metabolic reprogramming, autophagy, apoptosis, pyroptosis, and inflammation across organ-specific IRI models. We establish a unifying framework in which ALKBH5 functions as a double-edged sword, exerting either protective effects (such as sirtuin 1 (SIRT1) activation in the heart) or detrimental outcomes (such as tricarboxylic acid (TCA) cycle suppression), depending on tissue-specific microenvironments, disease stage dynamics, and downstream effector crosstalk (e.g., TCA cycle, SIRT1, PANoptosis). Despite its therapeutic potential, challenges in translation persist due to ALKBH5’s bidirectional effects and the lack of tissue-specific delivery systems. Future research should aim to resolve these controversies through advanced techniques such as single-cell m⁶A epitranscriptomics and develop spatiotemporally targeted modulators for precise intervention.